Payment overview · 2025
General Payments
$319.36
18 reported records · 10 companies
Healthcare provider profile · identity verified
Kimberly D. Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROLLA, MO · NPI 1396717104
Verified facts
What the public records show
CMS Open Payments records show Kimberly D. Johnson, MD received $319.36 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.34 | 22.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $60.71 | 19.0% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $48.26 | 15.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.90 | 8.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.69 | 7.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.22 | 7.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.95 | 5.6% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.36 | 5.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.47 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.46 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $319.36 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $60.71 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $48.26 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.90 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
91 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 752 | 588 |
| Atorvastatin Calcium | Atorvastatin Calcium | 356 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 224 | 42 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 209 | 209 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 33 |
| Gabapentin | Gabapentin | 189 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 28 |
| Jardiance | Empagliflozin | 167 | 20 |
| Lisinopril | Lisinopril | 157 | 38 |
| Omeprazole | Omeprazole | 128 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 20 |
| Losartan Potassium | Losartan Potassium | 116 | 21 |
| Alprazolam | Alprazolam | 111 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 102 | 24 |
| Potassium Chloride | Potassium Chloride | 98 | 18 |
| Trazodone Hcl | Trazodone Hcl | 96 | 19 |
| Trulicity | Dulaglutide | 91 | 13 |
| Metformin Hcl Er | Metformin Hcl | 87 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 17 |
| Meloxicam | Meloxicam | 81 | 13 |
| Furosemide | Furosemide | 79 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 72 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 12 |
| Ozempic | Semaglutide | 63 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 63 | suppressed |
| Pregabalin | Pregabalin | 60 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | suppressed |
| Celecoxib | Celecoxib | 57 | 11 |
| Famotidine | Famotidine | 57 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 55 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 54 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | suppressed |
| Eliquis | Apixaban | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Metformin Hcl | Metformin Hcl | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 12 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $319.36 · 18 records | PFIZER INC. | ABRYSVO, BRIXADI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, MOUNJARO, NURTEC ODT, PREVNAR 20, REXULTI, SUBLOCADE, VIVITROL, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error